Dr. Minbo Shim
Minbo Shim, MD
 Contact
Research collaboration

Intratympanic LP-PRP for Hearing Loss

11 years of clinical observation data. Three U.S. patents. Looking for an academic partner to lead a rigorous institutional study.

Discuss collaboration View data summary
Clinical observation summary

Single-center audiometric data — 2015–2026.

Retrospective, single-operator. Not a controlled trial. Detailed anonymized data available under research agreement.

104
Ears treated
40 acute · 64 chronic SNHL
14.2 dB
Mean ΔPTA improvement
All frequencies p < 0.001
12.2 dB
Chronic cohort ΔPTA
50% responder rate ≥ 10 dB
0.72–1.83
Cohen's dz
Large to very large
Key finding: Recovery persists across symptom durations up to 50 years (ρ = −0.018, p = 0.90). In the > 10-year stratum: ΔPTA 21.1 dB, 62% responder rate — incongruent with the natural history of chronic SSNHL. Full figures and frequency-level analysis available upon discussion.
Possible study designs

Institution-led, IRB-approved, your team.

Research-only patent license provided for the study. Authorship by actual contribution.

1

Pilot feasibility

Small prospective study — safety, workflow, endpoint selection, protocol reproducibility.

2

Prospective single-center

Defined inclusion criteria, audiologic endpoints, structured follow-up windows.

3

Randomized controlled trial

Intratympanic LP-PRP vs. standard care or appropriate comparator, if feasible.

Minbo Shim, MD

Board-certified ENT specialist, Seoul. 11 years clinical experience. Originator of the intratympanic LP-PRP protocol for SNHL and tinnitus.

Three U.S. utility patents, two Russian patents. Invited speaker, The Stem Cell Conference (Las Vegas, June 2026).

Proposed role: Protocol originator, clinical advisor, data source. Institutional team leads the study.

Let's discuss

Open to a brief Zoom call or in-person meeting during my U.S. visit in early June 2026.

Send inquiry
minboshim.com/research